Millipore Sigma Vibrant Logo

521235 PDGFR Tyrosine Kinase Inhibitor VI, SU6668 - CAS 210644-62-5 - Calbiochem

View Products on Sigmaaldrich.com
521235
  
Prix en cours de récupération
Le prix n'a pas pu être récupéré
La quantité minimale doit être un multiple de
Maximum Quantity is
À la validation de la commande Plus d'informations
Vous avez sauvegardé ()
 
Demander le prix
Disponibilité limitée
Disponibilité limitée
En stock 
Interrompu(e)
Disponible en quantités limitées
Disponibilité à confirmer
    Pour le restant : Nous vous tiendrons informé
      Pour le restant : Nous vous tiendrons informé
      Nous vous tiendrons informé
      Contacter le Service Clients
      Contact Customer Service

       

      Contacter le Service Clients

      Aperçu

      Replacement Information

      Tableau de caractéristiques principal

      CAS #Empirical Formula
      210644-62-5C₁₈H₁₈N₂O₃
      Description
      Overview

      This product has been discontinued.



      A cell-permeable indolinone compound that acts as a potent ATP-competitive inhibitor against RTKs (receptor tyrosine kinases) Kit, PDGFRβ, VEGFR2 (Flk-1/KDR), FGFR1 activity in vitro (IC50 = 0.01, 0.1, 3.9, and 3.8 µM, respectively) and PDGF/VEGF/bFGF-mediated angiogenesis and tumor development in vivo. Although initially characterized as an RTK inhibitor, SU6668 is now also known to target ser/thr kinases Aurora A, Aurora B, TBK1 (NAK/T2K), and AMPK (IC50 = 0.85, 0.047, 1.4, and 1.8 µM, respectively), as well as non-receptor TKs Lyn and Yes (IC50 = 4.3 and 5.8 µM, respectively).

      Catalogue Number521235
      Brand Family Calbiochem®
      Synonyms(Z)-3-(2,4-Dimethyl-5-(2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-1H-pyrrol-3-yl)-propionic acid, mTOR Inhibitor X, Aurora Kinase Inhibitor IV, VEGFR Tyrosine Kinase Inhibitor XXVII, VEGFR2 Kinase Inhibitor XXV
      References
      ReferencesGodl, K., et al. 2005. Cancer Res. 65, 6919.
      Laird, A.D., et al. 2002. FASEB J. 16, 681.
      Krystal, G.W., et al. 2001. Cancer Res. 61, 3660.
      Smolich, B.D., et al. 2001. Blood 97, 1413.
      Laird, A.D., et al. 2000. Cancer Res. 60, 4152.
      Shaheen, R.M., et al. 1999. Cancer Res. 59, 5412.
      Sun, L. et al. 1999. J. Med. Chem. 42, 5120.
      Product Information
      CAS number210644-62-5
      FormDark yellow solid
      Hill FormulaC₁₈H₁₈N₂O₃
      Chemical formulaC₁₈H₁₈N₂O₃
      Structure formula ImageStructure formula Image
      Quality LevelMQ100
      Applications
      Biological Information
      Purity≥97% by HPLC
      Physicochemical Information
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      R PhraseR: 22-36/37/38

      Harmful if swallowed.
      Irritating to eyes, respiratory system and skin.
      S PhraseS: 26-36-45

      In case of contact with eyes, rinse immediately with plenty of water and seek medical advice.
      Wear suitable protective clothing.
      In case of accident or if you feel unwell, seek medical advice immediately (show the label where possible).
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Ambient Temperature Only
      Toxicity Harmful
      Storage +2°C to +8°C
      Protect from Light Protect from light
      Do not freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
      Packaging Information
      Packaged under inert gas Packaged under inert gas
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      Référence GTIN
      521235 0

      Documentation

      PDGFR Tyrosine Kinase Inhibitor VI, SU6668 - CAS 210644-62-5 - Calbiochem FDS

      Titre

      Fiche de données de sécurité des matériaux (FDS) 

      PDGFR Tyrosine Kinase Inhibitor VI, SU6668 - CAS 210644-62-5 - Calbiochem Certificats d'analyse

      TitreNuméro de lot
      521235

      Références bibliographiques

      Aperçu de la référence bibliographique
      Godl, K., et al. 2005. Cancer Res. 65, 6919.
      Laird, A.D., et al. 2002. FASEB J. 16, 681.
      Krystal, G.W., et al. 2001. Cancer Res. 61, 3660.
      Smolich, B.D., et al. 2001. Blood 97, 1413.
      Laird, A.D., et al. 2000. Cancer Res. 60, 4152.
      Shaheen, R.M., et al. 1999. Cancer Res. 59, 5412.
      Sun, L. et al. 1999. J. Med. Chem. 42, 5120.
      Fiche technique

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision06-April-2009 RFH
      Synonyms(Z)-3-(2,4-Dimethyl-5-(2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-1H-pyrrol-3-yl)-propionic acid, mTOR Inhibitor X, Aurora Kinase Inhibitor IV, VEGFR Tyrosine Kinase Inhibitor XXVII, VEGFR2 Kinase Inhibitor XXV
      DescriptionA cell-permeable indolinone compound that acts as a potent ATP-competitive inhibitor against RTKs (receptor tyrosine kinases) Kit, PDGFRβ, VEGFR2 (Flk-1/KDR), FGFR1 activity in vitro (IC50 = 0.01, 0.1, 3.9, and 3.8 µM, respectively) and PDGF/VEGF/bFGF-mediated angiogenesis and tumor development in vivo. Although initially characterized as an RTK inhibitor, SU6668 is now also known to target ser/thr kinases Aurora A, Aurora B, TBK1 (NAK/T2K), and AMPK (IC50 = 0.85, 0.047, 1.4, and 1.8 µM, respectively), as well as non-receptor TKs Lyn and Yes (IC50 = 4.3 and 5.8 µM, respectively).
      FormDark yellow solid
      Intert gas (Yes/No) Packaged under inert gas
      CAS number210644-62-5
      Chemical formulaC₁₈H₁₈N₂O₃
      Structure formulaStructure formula
      Purity≥97% by HPLC
      SolubilityDMSO (100 mg/ml)
      Storage Protect from light
      +2°C to +8°C
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
      Toxicity Harmful
      ReferencesGodl, K., et al. 2005. Cancer Res. 65, 6919.
      Laird, A.D., et al. 2002. FASEB J. 16, 681.
      Krystal, G.W., et al. 2001. Cancer Res. 61, 3660.
      Smolich, B.D., et al. 2001. Blood 97, 1413.
      Laird, A.D., et al. 2000. Cancer Res. 60, 4152.
      Shaheen, R.M., et al. 1999. Cancer Res. 59, 5412.
      Sun, L. et al. 1999. J. Med. Chem. 42, 5120.